Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Improved Assay Determines d-Xylose in Urine and Serum

By LabMedica International staff writers
Posted on 03 Dec 2014
A simple method for the evaluation of intestinal lactase activity in vivo has been developed and optimized in humans with potential advantages over current tests for the noninvasive diagnosis of lactase deficiency or hypolactasia.

The phloroglucinol assay is the current method for d-xylose determination in urine, plasma, or serum; however, its sensitivity is limited when low amounts of D-xylose are to be measured, such as in the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose).

Clinical chemists at the Universidad Autónoma de Madrid (Spain) obtained 25 human urine and venous blood samples from healthy subjects who attended a local hospital. D-xylose and gaxilose determination in urine and serum after oral gavage of gaxilose was performed in six hypolactasic subjects with lactase activity in small intestine biopsy of less than 10 U/g protein enrolled in a multicenter, open label, nonrandomized trial, designed to address the diagnostic performance of the gaxilose test.

D-xylose determination was carried out using a modification of the phloroglucinol method and the absorbance in the colorimetric assay of D-xylose was read using a double beam spectrophotometer (Hitachi, Tokyo, Japan) set at 554 nm. A method for gaxilose determination by gas chromatography (GC) was also optimized.

The linearity of the improved D-xylose assay ranged from 0.125 to 5.0 mg/L as compared to 5 to 200 mg/L by the original method. Accuracy at the lower limit of quantification (LOQ), 0.125 mg/L, was 0.97%/2.49% in spiked urine or serum. For other quality controls (QC), it was less than 1.27%. Intra- and inter-assay precision at LOQ were 6.02% and 6.45% for urine, and 8.86% and 10.00%, respectively, for serum and for other QC; precision was less than 2.15%. Linearity of gaxilose determination by GC was 3.90 to 195.17 mg/L for urine and 9.75 to 95.17 mg/L for serum with acceptable sensitivity and reproducibility. The method proved adequate for the D-xylose determination in healthy and hypolactasic subjects after oral administration of gaxilose.

The authors concluded that the modified method provides high sensitivity and robustness for D-xylose quantification in urine and serum samples for routine clinical use especially in the noninvasive diagnosis of intestinal lactase deficiency with the gaxilose test. The study was published in the November 2014 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

Universidad Autónoma de Madrid
Hitachi



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.